You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

SOJOURN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Sojourn, and what generic alternatives are available?

Sojourn is a drug marketed by Piramal Critical and is included in one NDA.

The generic ingredient in SOJOURN is sevoflurane. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sojourn

A generic version of SOJOURN was approved as sevoflurane by BAXTER HLTHCARE on July 2nd, 2002.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SOJOURN?
  • What are the global sales for SOJOURN?
  • What is Average Wholesale Price for SOJOURN?
Drug patent expirations by year for SOJOURN
Recent Clinical Trials for SOJOURN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alberta Children's HospitalPhase 2
Emory UniversityPhase 4
Alberta Children's HospitalPhase 1

See all SOJOURN clinical trials

Pharmacology for SOJOURN
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia

US Patents and Regulatory Information for SOJOURN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Critical SOJOURN sevoflurane LIQUID;INHALATION 077867-001 May 2, 2007 AN RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for SOJOURN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chanelle Pharmaceuticals Manufacturing Limited Sevohale (previously known as Sevocalm) sevoflurane EMEA/V/C/004199
For the induction and maintenance of anaesthesia.
Authorised yes no no 2016-06-21
Zoetis Belgium SA SevoFlo sevoflurane EMEA/V/C/000072
For the induction and maintenance of anaesthesia in dogs and cats.
Authorised no no no 2002-12-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.